@article{fcc1b0434bbb4593a4c8f68dc6ca87e1,
title = "Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population",
keywords = "Aromatase inhibitors, Breast neoplasm, Endocrine therapy, Everolimus, Post-menopausal women, Targeted therapy, PLACEBO-CONTROLLED TRIAL, ENDOCRINE THERAPY, POSTMENOPAUSAL WOMEN, DOUBLE-BLIND, SINGLE-ARM, FULVESTRANT, RESISTANCE, SAFETY, MULTICENTER, PALBOCICLIB",
author = "E. Ciruelos and G. Jerusalem and M. Martin and Tjan-Heijnen, {V. C. G.} and P. Neven and J. Gavila and F. Montemurro and D. Generali and I. Lang and Martinez-Serrano, {M. J.} and Perello, {M. F.} and P. Conte",
year = "2020",
month = oct,
doi = "10.1007/s12094-020-02327-5",
language = "English",
volume = "22",
pages = "1857--1866",
journal = "Clinical & Translational Oncology",
issn = "1699-048X",
publisher = "Springer",
number = "10",
}